The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.
Dr. Suneel Kamath discusses the ALASCCA study in colorectal cancer and highlighted the importance of next-generation sequencing and testing.
Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me.
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.
Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL ...
In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.
Dr. John Oertle discusses the key benefits to come from patients with cancer connecting with support networks, advocacy groups and resources.
The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine ...
As a cancer survivor, I face added stress with an upcoming black belt test and "scanxiety" before my annual CT scan and ...
Dr. Gabriel A. Brooks discusses the recent FDA product labeling update for Xeloda and 5-FU which aims to highlight risks associated with DPD deficiency.
THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback